AD‑HAFT included atopic dermatitis patients aged 12 years and older with moderate-to-severe hand and/or foot involvement inadequately controlled with or intolerant to topical Rx therapies who were randomized to DUPIXENT monotherapy or placebo for 16 weeks. The primary endpoint was the proportion of subjects with an IGA hand and foot score of 0 (clear) or 1 (almost clear) at Week 16. The key secondary endpoint was reduction of itch as measured by the hand and foot Peak Pruritus NRS (≥4-point improvement). The trial was unique as it used HECSI and HECSI‑75 measurements. HECSI is used in clinical trials to determine the rate of severity of 6 clinical signs of hand eczema and the extent of lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4‑point severity scale ranging from 0 (no skin changes) to 3 (severe disease) and a 5‑point scale rating the affected area(s) ranging from 0 (0% surface area affected) to 4 (76% to 100% surface area affected). HECSI‑75 represents an improvement of ≥75% in the Hand Eczema Severity Index.1,2,9